Department of Microbiology, Centre for Translational Microbiome Research, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
I-BioStat, Data Science Institute, Hasselt University, Hasselt, Belgium.
J Antimicrob Chemother. 2024 Mar 1;79(3):608-616. doi: 10.1093/jac/dkae012.
Antibiotics and proton pump inhibitors (PPI) are recognized risk factors for acquisition and recurrence of Clostridioides difficile infection (CDI), yet combined effects remain unclear.
To assess the short- and long-term effects of antibiotics and PPIs on CDI risk and recurrence.
Population-based study including all 43 152 patients diagnosed with CDI in Sweden (2006-2019), and 355 172 matched population controls without CDI. The impact of antibiotics and PPIs on CDI risk and recurrence was explored for recent (0-30 days) and preceding (31-180 days) use prior to their first CDI diagnosis, using multivariable conditional logistic regression presented as odds ratios (ORs) and 95% confidence interval, adjusted for demographics, comorbidities and other drugs.
Compared to controls, the combined effect of recent PPIs and antibiotics [ORAB+PPI = 17.51 (17.48-17.53)] on CDI risk was stronger than the individual effects [ORAB = 15.37 (14.83-15.93); ORPPI = 2.65 (2.54-2.76)]. Results were less pronounced for exposure during the preceding months. Dose-response analyses showed increasing exposure correlated with CDI risk [recent use: ORAB = 6.32 (6.15-6.49); ORPPI = 1.65 (1.62-1.68) per prescription increase].Compared to individuals without recurrence (rCDI), recent [ORAB = 1.30 (1.23-1.38)] and preceding [ORAB = 1.23 (1.16-1.31); ORPPI = 1.12 (1.03-1.21)] use also affected the risk of recurrence yet without significant interaction between both. Recent macrolides/lincosamides/streptogramins; other antibacterials including nitroimidazole derivates; non-penicillin beta lactams and quinolones showed the strongest association with CDI risk and recurrence, particularly for recent use. PPI use, both recent and preceding, further increased the CDI risk associated with almost all antibiotic classes.
Recent and less recent use of PPIs and systemic antibiotics was associated with an increased risk of CDI, particularly in combination.
抗生素和质子泵抑制剂(PPI)被认为是艰难梭菌感染(CDI)获得和复发的危险因素,但联合作用仍不清楚。
评估抗生素和 PPI 对 CDI 风险和复发的短期和长期影响。
这是一项基于人群的研究,纳入了瑞典所有 43152 例 CDI 确诊患者(2006-2019 年)和 355172 例无 CDI 的匹配人群对照。使用多变量条件逻辑回归,以比值比(OR)和 95%置信区间表示,调整了人口统计学、合并症和其他药物因素,探讨了近期(0-30 天)和之前(31-180 天)使用抗生素和 PPI 对首次 CDI 诊断前的 CDI 风险和复发的影响。
与对照组相比,近期 PPI 和抗生素联合使用(ORAB+PPI=17.51 [17.48-17.53])对 CDI 风险的综合影响强于单独使用(ORAB=15.37 [14.83-15.93];ORPPI=2.65 [2.54-2.76])。在之前的几个月中,暴露的结果不太明显。剂量反应分析表明,暴露量的增加与 CDI 风险相关[近期使用:ORAB=6.32 [6.15-6.49];ORPPI=1.65 [1.62-1.68],每增加一次处方]。与无复发个体(rCDI)相比,近期[ORAB=1.30 [1.23-1.38]]和之前[ORAB=1.23 [1.16-1.31];ORPPI=1.12 [1.03-1.21]]使用也会增加复发的风险,但两者之间没有显著的相互作用。近期大环内酯类/林可酰胺类/糖肽类;其他抗菌药物包括硝基咪唑衍生物;非青霉素类β-内酰胺类和喹诺酮类与 CDI 的风险和复发相关性最强,特别是近期使用。近期和之前的 PPI 使用进一步增加了与几乎所有抗生素类别相关的 CDI 风险。
近期和不太近期使用 PPI 和全身抗生素与 CDI 风险增加相关,尤其是联合使用时。